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Objective: To assess the relationship of patients' medication beliefs and treatment complexity with unintentional
and intentional non-adherence for three therapeutic groups commonly used by patients with type 2 diabetes.
Methods: Survey data about adherence (Medication Adherence Report Scale) and beliefs about medicines (Beliefs
about Medicines Questionnaire) were combined with prescription data from the Groningen Initiative to ANalyse
Type 2 diabetes Treatment (GIANTT) database. Patients were classiﬁed as being adherent, mainly unintentional
non-adherent, or partly intentional non-adherent per therapeutic group (glucose-, blood pressure-, and lipid-
lowering drugs). Treatment complexitywasmeasured using theMedication Regimen Complexity Index,which in-
cludes the dosage form, dosing frequency and additional directions of taking the drug. Analyses were performed
using Kruskal–Wallis and Mann–Whitney U-tests.
Results:Of257 contacted patients, 133 (52%) returned the questionnaire. The patients had amean age of 66 years
and 50% were females. Necessity beliefs were not signiﬁcantly different between the adherers, mainly uninten-
tional non-adherers, and partly intentional non-adherers (differences smaller than 5 points on a scale from 5 to
25). For blood pressure-lowering drugs, patients reporting intentional non-adherence had higher concern beliefs
than adherers (8 point difference, P = 0.01). Treatment complexity scores were lower for adherers but similar
for mainly unintentional and partly intentional non-adherers to glucose- and blood pressure-lowering drugs.
Conclusion: Treatment complexity was related to non-adherence in general. Beliefs about necessity were not
strongly associated with non-adherence, while patients' concern beliefs may be associated with intentional
non-adherence. However, the role of these determinants differs per therapeutic group.© 2013 Elsevier Inc. All rights reserved.Introduction
Although a drug should be taken as prescribed to achieve its
intended effectiveness, adherence to drug therapy is a well-known
problem in clinical practice [1–3]. Patients can be intentional as well
as unintentional non-adherent to their drug treatment [4–6]. Intention-
al non-adherence is seen as a conscious decision for not taking the drug
as prescribed after balancing the pros and cons, whereas unintentional
non-adherence is a more passive behavior which is more strongly asso-
ciated with demographics [3,6]. Non-adherence is inﬂuenced by many
factors, including patient and treatment characteristics [3,7]. Of thearmacology (FB20), University
en, The Netherlands. Tel.: +31
j.keers@mzh.nl (J.C. Keers),
e Zeeuw),
oorham01@umcg.nl
ghts reserved.modiﬁable factors, beliefs about a drug and treatment convenience or
complexity are important predictors of non-adherence [7–10].
Within the belief domain it is relevant to distinguish between con-
cern and necessity beliefs [11]. Concern beliefs are about the adverse
consequences of taking a drug, whereas necessity beliefs are about the
positive effects of a drug on someone's health [12]. Little is known
about the inﬂuence of these different beliefs on unintentional versus in-
tentional non-adherence. Two studies showed that concern and necessi-
ty beliefs were associatedwith intentional non-adherence, whereas only
one study found that concern beliefs were associated with unintentional
non-adherence [4,13]. In these studies, however, people using different
therapeutic groupswere combined. Another study showed that the asso-
ciation between beliefs and types of non-adherence can differ across
therapeutic groups [7].
Focusing on different therapeutic groups also has implications for
the treatment complexity. Treatment complexity includes the number
of drugs that have to be taken, the route of drug administration, dosing
frequency, and additional directions of taking the drug [14]. Higher
treatment complexity is associated with lower rates of optimal
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to a once-daily than a twice-daily regime [15,16] and a study using a
composite score of drug administration, dosing frequency and addition-
al directions found that patients with low complexity scores were more
often adherent than patients with high complexity scores [17]. At pres-
ent, it is not known how this association varies for unintentional or in-
tentional non-adherence.
Patients with type 2 diabetes are often treatedwith drugs frommul-
tiple therapeutic groups, including glucose-, blood pressure-, and lipid-
lowering drugs [18]. Previously, it was shown that patients with type 2
diabetes reported more often unintentional non-adherence to the
glucose-lowering drugs than the blood pressure- and lipid-lowering
drugs, and that intentional non-adherence did not differ among the
therapeutic groups [19]. The aim of the current study is to assess the
role of different kinds of beliefs (necessity and concern) and treatment
complexity on unintentional and intentional non-adherence, and
whether this differs for glucose-, blood pressure-, and lipid-lowering
drugs in patients with type 2 diabetes.
Method
In this study, cross-sectional survey data were collected in 2007,
whichwere combinedwith prescription data collected in theGroningen
Initiative to ANalyse Type 2 diabetes Treatment (GIANTT)-project [20].
The GIANTT-project is a regional initiative of health care professionals
and researchers focusing on the primary care of patients with type 2 di-
abetes in the province of Groningen in The Netherlands. The study was
carried out in accordance with the Code of Ethics of the World Medica-
tion Association (Declaration of Helsinki) for experiments involving
humans. Ethical approval was not needed for this study, as determined
by The Medical Ethics Committee of the University Medical Center
Groningen in the Netherlands.
Participants
Of the 32 general practitioners (GPs) included in the GIANTT-project
in 2006, 19 GPs (59%) agreed to recruit patients for this study. For these
19 GPs, we selected a total of 345 patients with type 2 diabetes from the
GIANTT-database who had been prescribed an oral glucose-lowering
drug in 2005. To recruit a balanced group of adherent and non-
adherent participants, half of the patients were selected based on a
medication possession ratio (MPR) b80% of their oral glucose-lowering
drug indicating possible low adherence [21]. Of the345 selected patients,
69 (20%) were excluded from the study by their GP because of: psycho-
social problems (14), language issues (13), cognitive limitations (10),
patient died (8), patient moved (6), GP expects unwillingness (4), seri-
ous comorbidity (3), admission to hospital or nursing home (3), or
other reasons (8). The remaining 257 patients were contacted by mail,
and those who gave informed consent received a survey composed of
general questions and validated questionnaires assessing beliefs and
adherence which were applied to glucose-, blood pressure-, and lipid-
lowering drugs. Patients were asked to report the name of their
glucose-lowering drugs, and when applicable, their blood pressure-
and lipid-lowering drugs. In addition, patients were asked to indicate
whether they self-measured their glucose levels, their blood pressure,
and whether their lipid-levels had been measured without a GP order.
Beliefs
Patients' beliefs about the three therapeutic groups were assessed
using the Beliefs about Medicines Questionnaire (BMQ) speciﬁc [12].
The BMQ contains 5 items about necessity beliefs (e.g. ‘My health at
present depends onmy glucose-lowering drugs’), and 5 items about con-
cern beliefs (e.g. ‘I sometimes worry about becoming too dependent on
the glucose-lowering drugs’). Participants indicate their agreement with
each item on a 5-point Likert scale, ranging from totally disagree tototally agree. Scores on items per subscale were summed, ranging
from 5 (totally agree) to 25 (totally disagree) for the necessity and con-
cern subscales. Internal consistency was assessed using Cronbach's α.
For those patients included in the analyses of glucose-lowering drugs,
the internal consistencywas .721 and .777 for the necessity and the con-
cern subscales, respectively. These values were .834 and .823, and .779
and .828 for the patients included in the analyses of respectively blood
pressure-, and lipid-lowering drugs. Besides the assessment of concern
and necessity beliefs, the necessity–concern differential was measured.
This differential gives an indication of which beliefs the patient weighs
more heavily [4].
Treatment complexity
In the questionnaire, patients reported which glucose-, blood
pressure-, and lipid-lowering drugs they had used in the previous
3 months. Dosing information on the drugs was derived from the
GIANTT-database. A treatment complexity score was computed for
each reported drug using the Medication Regimen Complexity Index
[14]. For each patient using more than one drug within a therapeutic
group, the scores of the Medication Regimen Complexity Index were
combined resulting in one complexity score per therapeutic group.
The Medication Regimen Complexity Index takes into account the dos-
age form, dosing frequency and additional directions of taking the drug.
For the dosage form, the scores 1 and 3 were used for tablets and
injections, respectively. The dosing frequency was registered in the
GIANTT-database. The following additional directions were included
in the complexity score based on additional dosing information in the
GIANTT-database: break or crush a tablet, intake of multiple units at
one time, variable dosing, and alternating dosing. Two researchers
(SdV and PD) independently computed the complexity score for each
patient. The researchers agreed on 96%, 100% and 99% of the scores for
the patients using glucose-, blood pressure-, and lipid-lowering drugs,
respectively. All disagreements were solved by discussion between
the researchers.
Adherence
Adherence was assessed using the Medication Adherence Report
Scale (MARS) [22]. The MARS contains one item that reﬂects uninten-
tional non-adherence (‘I forget to take my glucose-lowering drugs’) and
four items that largely reﬂect different forms of intentional non-
adherence (e.g. ‘I alter the dose of my glucose-lowering drugs’) [4,22].
Participants indicate how often each statement applied to them in
the last 3 months on a 5-point Likert scale ranging from always to
never. Cronbach's α values were .715, .595 and .699 for intentional
non-adherence to respectively glucose-, blood pressure-, and lipid-
lowering drugs. The intentional non-adherence items were summed.
Non-adherence was deﬁned as a score of lower than the maximum of
5 for unintentional and lower than the maximum of 20 for intentional
non-adherence, indicating any degree of non-adherence.
Statistical analyses
Analyseswere conducted per therapeutic group, including data from
those patients who reported the name of their drug in the correct ther-
apeutic group, who completed all MARS-questions, who had no more
than one missing value at the belief questions, and for whom drug dos-
ing information was available in the database. For the patients with one
missing value for the belief questions, the value was imputed using the
median value of the other patients for that item. Since the median
values are used to test for differences between groups (see below),
this method does not affect the median value of the whole sample for
that item.
Per therapeutic group, patientswere divided into being fully adherent,
mainly unintentional non-adherent, or in part intentional non-adherent.
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non-adherence but may also report to be unintentional non-adherent.
Differences in patient characteristics between adherers, mainly uninten-
tional non-adherers and partly intentional non-adherers were tested
using Pearsonχ2-tests, one-way analyses of variance, and Kruskal–Wallis
tests, dependingon thedistributionof the variables. Associations between
beliefs and (un)intentional non-adherence, and treatment complexity
and (un)intentional non-adherence were tested using Kruskal–Wallis
tests. A P-value b 0.05 was considered statistically signiﬁcant. Mann–
Whitney U-tests with Bonferroni adjustment to correct for multiple test-
ing (a P-value ≤ 0.01 was considered statistically signiﬁcant) were used
for subsequent testing for differences between two speciﬁc groups. All
analyses were conducted using IBM SPSS Statistics version 20 (Armonk,
New York, USA).Forget Alter dose Stop taking Decide to
miss out
Take less than
instructed
Fig. 1. Percentage of patients reporting different types of non-adherence per therapeutic
group.Results
Of the 257 contacted patients, 133 (52%) returned the questionnaire. Half of these
patients were female, and the mean age was 66 years (Table 1). Patients included in the
analyses with the glucose-lowering drugs had longer diabetes duration than those that
were not included. No other differences were found between patients included in the
analyses per therapeutic group and those that were not included in the analyses (Supple-
mental Table 1).
Of the patients reporting non-adherence to their drugs, almost all patients reported to
be at least unintentional non-adherent (Fig. 1). Intentional non-adherers to glucose- or
blood pressure-lowering drugs more often reported to alter their dose or take less than
instructed than the intentional non-adherers to lipid-lowering drugs. Patients who were
intentional non-adherent to their lipid-lowering drugs more often reported that they
stopped taking the drug (Fig. 1).
We observed no signiﬁcant differences between fully adherent, mainly unintentional
non-adherent and partly intentional non-adherent patients in age, gender, education
level, and diabetes duration. However, intentional non-adherers to glucose-lowering
drugs more often self-measured their glucose levels than adherent patients (P b 0.01)
(Supplemental Table 2). In addition, they had a higher bodymass index than the uninten-
tional non-adherers to these drugs (P b 0.01).Beliefs and non-adherence
For all three therapeutic groups, no signiﬁcant differences in necessity beliefs were
found between the adherers and unintentional and intentional non-adherers (Table 2).
For glucose-lowering drugs, the median necessity scores showed only 1 point difference,
whereas this was 1.5 point for blood-pressure and 4 points for lipid-lowering drugs. In
general, higher necessity beliefs were reported for the glucose-lowering drugs than for
the blood pressure- and lipid-lowering drugs.
Intentional non-adherers to glucose- and blood pressure-lowering drugs had more
concerns about these drugs than the adherers and unintentional non-adherers, which
was only statistically signiﬁcant for the bloodpressure-lowering drugs (P b 0.05). Theme-
dian concern scores showed differences of 2.5 points for glucose-lowering drugs, 8 points
for blood pressure-lowering drugs, and 0 points for lipid-lowering drugs. The signiﬁcant
difference for the blood pressure-lowering drugs was mainly due to the difference be-
tween the adherers and intentional non-adherers (P = 0.01).
The adherent and the unintentional non-adherent patients weighed the necessity of
their drug use heavier than their concerns about these drugs, as shown by the positive
necessity–concern-differential (Table 2). This ﬁnding applied for the three therapeutic
groups. For the intentional non-adherers to blood pressure- and lipid-lowering drugs,
however, concerns weighed more heavily than necessity.Table 1
Patient characteristics per therapeutic group.
Total (N = 133) Glucose-lowering drugs (N = 8
Females (%) 66 (49.6) 38 (44.7)
Mean age in years (SD) 66.3 (9.6) 65.8 (9.5)
Education (%)
Low education 70 (53.0) 41 (48.8)
Middle education 29 (22.0) 23 (27.4)
High education 25 (18.9) 15 (17.9)
Other 8 (6.1) 5 (6.0)
Mean BMI (SD) 29.3 (4.3) 29.0 (4.0)
Median diabetes duration (IQR) 7 (4.0–10.0) 7 (5.0–11.0)
Measurement outside GPs ofﬁce
Yes (%) 22 (27.2)
GPs = General practitioners; BMI = Body mass index; SD = Standard deviation; IQR = InterTreatment complexity and non-adherence
Treatment complexity scores were lower for adherers than non-adherers to glucose-
(P b 0.05) and blood pressure-lowering drugs (P b 0.05) (Table 2). For all three therapeu-
tic groups, no differences in complexity scores were seen between the unintentional and
intentional non-adherers (Table 2).
Discussion
This study shows that treatment complexity is related with non-
adherence to glucose- and blood pressure-loweringdrugs,which is sim-
ilar for patients reporting mainly unintentional or partly intentional
non-adherence. Patient beliefs have a more complex association with
non-adherence. Concerns were higher in case of intentional non-
adherence for blood pressure-lowering and glucose-lowering drugs
but this ﬁnding was only signiﬁcant for the blood pressure-lowering
drugs. Beliefs about necessity did not show much difference among
the adherence groups for glucose-lowering and blood pressure-
lowering drugs. For lipid-lowering drugs, the difference in necessity be-
liefs among the adherence groups was larger but also non-signiﬁcant.
Concerns were more heavily weighed than necessity by intentional
non-adherers to blood pressure- and lipid-lowering drugs, whereas ne-
cessity was more heavily weighed by intentional non-adherers to
glucose-lowering drugs. Previous studies showed inconsistent associa-
tions between beliefs and (un)intentional non-adherence [4,13]. The
current data suggests that this inconsistency may be due to differences
across therapeutic groups.
Patients with type 2 diabetes differ in their concerns and beliefs
about necessity across the three therapeutic groups. As has been
observed before, necessity is believed to be higher for glucose-
lowering drugs (median score 20) than for blood pressure-lowering5) Blood pressure-lowering drugs (N = 67) Lipid-lowering drugs (N = 85)
34 (50.7) 39 (45.9)
65.9 (10.1) 65.7 (9.9)
32 (48.5) 42 (50.0)
17 (25.8) 22 (26.2)
13 (19.7) 14 (16.7)
4 (6.1) 6 (7.1)
29.7 (4.7) 29.2 (4.3)
7 (5.0–11.0) 7 (3.0–10.0)
18 (26.9) 8 (9.4)
quartile range.
Table 2
Beliefs and treatment complexity for glucose-, blood pressure-, and lipid-lowering drugs according to adherence.
All Adherent Unintentionally non-adherent Intentionally non-adherent P-valuea
Glucose-lowering drugs N = 85 N = 53 N = 22 N = 10
Differential median (IQR) 8.0 (4.0–13.0) 8.0 (3.0–11.0) 8.5 (5.8–15.0) 8.0 (0.5–13.8) .370
Median (IQR) of necessity beliefs (scale 5–25) 20.0 (17.0–22.0) 20.0 (16.5–22.0) 21.0 (18.8–23.0) 20.0 (15.8–24.0) .152
Median (IQR) of concern beliefs (scale 5–25) 11.0 (9.0–14.0) 11.0 (9.0–14.0) 10.5 (8.8–13.3) 13.0 (7.8–16.5) .516
Median (IQR) of treatment complexity scores 6 (3.0–7.5) 4 (3.0–7.0) 7 (5.5–7.3) 7.5 (2.8–13.0) .126⁎⁎
Blood pressure-lowering drugs N = 67 N = 53 N = 10 N = 4
Differential median (IQR) 5.0 (2.0–9.0) 5.0 (2.0–10.0) 7.0 (1.8–9.5) −0.5 (−4.8–5.3) .152
Median (IQR) of necessity beliefs (scale 5–25) 17.0 (14.0–20.0) 17.0 (14.5–20.0) 15.5 (13.0–22.3) 17.0 (12.0–21.3) .855
Median (IQR) of concern beliefs (scale 5–25) 11.0 (9.0–14.0) 11.0 (9.0–13.0) 9.0 (7.8–14.3) 17.0 (13.5–19.8) .037⁎
Median (IQR) of treatment complexity scores 3 (2.0–5.0) 3 (2.0–4.0) 4 (3.8–6.0) 4 (4.0–4.8) .050⁎⁎⁎
Lipid-lowering drugs N = 85 N = 67 N = 15 N = 3
Differential median (IQR) 3.0 (0.0–7.0) 4.0 (0.0–7.0) 2.0 (0.0–7.0) −1.0b .459
Median (IQR) of necessity beliefs (scale 5–25) 15.0 (11.5–18.0) 15.0 (12.0–18.0) 14.0 (10.0–18.0) 11.0b .347
Median (IQR) of concern beliefs (scale 5–25) 11.0 (9.0–14.0) 11.0 (9.0–14.0) 11.0 (8.0–14.0) 11.0b .779
Median (IQR) of treatment complexity scores 2 (2.0–2.0) 2 (2.0–2.0) 2 (2.0–2.0) 2 (2.0–2.0) .884
IQR = Interquartile range.
a Kruskal–Wallis test.
b No IQR due to low numbers.
⁎ Signiﬁcance due to difference between adherers and intentional non-adherers (P = 0.01).
⁎⁎ Signiﬁcant difference between adherers and non-adherers (P = 0.04).
⁎⁎⁎ Signiﬁcant difference between adherers and non-adherers (P = 0.01).
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whereas no differences are seen across the therapeutic groups for
concerns, with median scores of 11 for all three groups [23]. These
differences in necessity beliefs among the therapeutic groups may be
explained using Leventhal's self-regulatory model of illness cognitions
[24]. Patients perceive more (personal) control, symptoms, and
emotional distress in type 2 diabetes than either hypertension or
hyperlipidemia [23].
Previously, it was found that for intentional non-adherers, concerns
play a more important role than beliefs about the necessity of the drug
[4]. This result was conﬁrmed in the current study for the blood
pressure-lowering drugs, where a negative necessity–concern differen-
tial correspondedwith strong concern beliefs in the group of intentional
non-adherers. For glucose-loweringdrugs, ourﬁndings indicate a differ-
ent mechanism with a positive necessity–concern differential and less
strong concern beliefs in intentional non-adherers. This ﬁnding may
be explained by a different type of intentional non-adherence for
these drugs. We found that these patients often altered doses or took
less than instructed, which could be driven by self-management. Self-
measurement of glucose-levels was signiﬁcantly related to intentional
non-adherence to glucose-lowering drugs. One may doubt whether
we should talk here of non-adherence, since the changes in drug use
may be the result of the self-management. Consequently, intentional
non-adherence to glucose-lowering drugs might be overestimated
when self-management is not taken into account. For lipid-lowering
drugs, a negative necessity–concern differential was found for the in-
tentional non-adherers. Concern beliefswere, however, similar in all ad-
herence groups. Previously, it has been concluded that concerns about
or experiences with adverse events are the most common reason for
statin discontinuation [25]. Our ﬁndings suggest that also people who
continue statin treatment may have similar concerns.
The current study conﬁrms previous results that treatment complex-
ity is related to non-adherence in general [10,17]. We did not observe
any difference between patients who reported mainly unintentional
non-adherence and those reporting partly intentional non-adherence.
For lipid-lowering drugs, treatment complexity was not associated
with non-adherence in general since complexity scores were low in all
three groups.
Some limitations of this study need to be acknowledged. First of all,
this is a cross-sectional study, whichmakes it impossible to draw causal
inferences. Medication beliefs and treatment complexity can be expect-
ed to inﬂuence adherence but may also change in patients after theyhave become non-adherent. A self-report measure of adherence was
used because self-report is the only method that can be used to distin-
guish between intentional and unintentional non-adherence [26,27].
Only the item on forgetting to take the drug is considered to reﬂect
mainly unintentional non-adherence, whereas all other items are con-
sidered as reﬂecting largely intentional non-adherence [4,22]. The inter-
nal consistency of the intentional non-adherence items ranged from 0.6
to 0.7, indicating the need for better measures of intentional non-
adherence. Currently, however, we lack better self-reportedmedication
adherence measures [27]. The use of self-reported adherence measure-
ment may lead to underestimations of non-adherence especially inten-
tional non-adherence, because of socially desirable answering and recall
bias when completing the questionnaire [26,28]. A study that compared
self-reports of adherence with more objective instruments (e.g. pill
counts, electronic monitors) found moderate to high agreement in ad-
herence rates among the measures [29]. Although intentional non-
adherence was assessed using four different types of non-adherence,
only a small number of patients reported to be intentional non-
adherent to the blood pressure- and lipid-lowering drugs. This low
number limited the power to detect differences of less than 3 to 4 points
on the belief scales for glucose- and blood pressure-lowering drugs and
less than 5 points for lipid-lowering drugs as being signiﬁcant. In addi-
tion, the results of intentional non-adherers should be interpreted
with caution since patients who reported both unintentional and
intentional non-adherence were classiﬁed as being intentional non-
adherent. The low number of patients in this study made it impossible
to classify this behavior in a separate group. Possible selection bias of pa-
tients due to the moderate response rate could be another limitation of
this study. Participating patients were, however, comparable in general
patient characteristics to other patients with type 2 diabetes in Dutch
primary care [30]. Patients with inadequate survey or prescription
data had to be excluded from the analyses. These patients did not differ
from the other patients in age, gender, education level and body mass
index, but for the glucose-lowering drugs included patients had longer
diabetes duration. Furthermore, the use of other drugs then diabetes
and cardiovascular risk management related drugs were not taken
into account in the treatment complexity scores.
The strength of our study is that we evaluated the association be-
tween determinants and types of non-adherence for different therapeu-
tic groups within the same population of patients. This approach
prevents that differences in determinants are inﬂuenced by other differ-
ences in the patient population.
138 S.T. de Vries et al. / Journal of Psychosomatic Research 76 (2014) 134–138To conclude, addressing concerns about drugs appears to be more
important than stressing the necessity of treatment in patients with di-
abetes. Concerns seem to be associatedwith intentional non-adherence
to especially blood pressure-lowering drugs but not with unintentional
non-adherence. Beliefs about necessity showed no clear association
with either type of non-adherence. Treatment complexity was relevant
for any non-adherence to glucose- and blood pressure-lowering drugs,
and health care professionals should thus try to avoid complex regi-
mens asmuch as possible. Finally, our study indicates that determinants
do not only differ among types of non-adherence, but also differ across
therapeutic groups. Fighting non-adherence asks for more than a one-
size ﬁts all approach.
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